Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Nonvenereal Syphilis Treatment Market size was over USD 332.06 million in 2024 and is anticipated to cross USD 1.01 billion by 2037, growing at more than 8.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of nonvenereal syphilis treatment is estimated at USD 381.03 million.
The growth of the market can be attributed to the improving coverage and accuracy of nonvenereal syphilis testing worldwide as well as the development of a novel rapid, point-of-care test (POCT) for confirmatory testing of active syphilis infection with the rising concern about the globally increasing transmission of bejel, especially among children living in tropical, subtropical, or warm arid climates, predominantly by direct contact. As per the World Health Organization data, more than 80,000 cases of bejel are reported every year worldwide.
Nonvenereal syphilis is an infectious disease common in some parts but rare in many parts of the world. The bejel infection is very similar to syphilis but its means of transmission typically comprises non-sexual skin contact or the common use of eating and drinking utensils against that of syphilis that is sexually transmitted. Concern about the spreading spiral bacteria of the genus Treponema has led to the increasing effort taken by governments as well as healthcare professionals worldwide to develop accurate diagnostic tools for the identification of infections caused by T. pallidum subspecies so that their treatments can be developed accordingly, which is expected to bring in revenue boost for the key market players in the nonvenereal syphilis treatment market.
Nonvenereal Syphilis Treatment Sector: Growth Drivers and Challenges
Growth Drivers
-
Rising Prevalence of Infectious Diseases – diseases such as syphilis, bejel, pinta, and yaws are rare but it’s increasing prevalence worldwide is leading to surging investments in its prevention & treatment which is expected to boost the growth of the nonvenereal syphilis treatment market in the projected years. Centers for Disease Control and Prevention unveiled that in 2019 around 129,813 cases of all stages of syphilis, were reported worldwide.
-
Growing Burden of Incidences Associated with Bacterial Pathogens – as per a study nearly 7·7 million deaths globally were associated with 33 different bacterial pathogens (both resistant and susceptible to antimicrobials), which comprised nearly 13·6% of all global deaths and 56·2% of all sepsis-related deaths in 2019. Owing to these widespread concerns about bacterial pathogens, the government of various countries is joining hands to eradicate diseases caused by different pathogens, which will indirectly result in improved rapid diagnostic tests to detect syphilis and nonvenereal syphilis and its treatment.
-
Rising Cases of Diseases Caused by Treponema species – diseases such as yaws are gaining prevalence, mostly in children. It is observed that nearly 75–80% of people affected by yaws are children under 15 years of age with peak incidences occurring in children aged 6–10 years. Hence, this has elevated research on medications and treatment of diseases caused by Treponema species that also cause bejel, and pinta and is morphologically and serologically indistinguishable from the agent syphilis This, as a result, is expected to propel the market growth in the projected years.
-
Strategies to Eradicate Neglected Tropical Diseases – World Health Organization (WHO) has drawn a 2021-2030 roadmap for the eradication of rare tropical diseases which include syphilis, yaws, and bejel to attain the Sustainable Development Goals. The roadmap was prepared through an extensive global consultation pursuant to decision EB146(9) of the Executive Board at WHO’s 146th session in February 2020.
Challenges
-
Persistent Challenges in the Diagnostic Landscape and Testing Models – are hindering global nonvenereal syphilis control efforts. The challenges in the diagnosis of active syphilis infection, bejel, yaws, and pinta diseases owing to insufficient research and development in key areas and the present technological, individual, and structural barriers in access to nonvenereal syphilis testing is a major restraining factor of nonvenereal syphilis treatment market.
-
Lack of Highly Trained Laboratory Technologists and Complex/ Expensive Laboratory Instruments
-
Lack of Healthcare Infrastructure
Nonvenereal Syphilis Treatment Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
8.9% |
|
Base Year Market Size (2024) |
USD 332.06 million |
|
Forecast Year Market Size (2037) |
USD 1.01 billion |
|
Regional Scope |
|
Nonvenereal Syphilis Treatment Segmentation
Treatment (Antibiotics, Topical Treatment)
The global nonvenereal syphilis treatment market is segmented and analyzed for demand and supply by treatment into antibiotics and topical treatment. Out of these segments, the antibiotics segment is estimated to gain the largest market share in the year 2037. The major factors applicable to the growth of the segment include the rapidly developing spectrum of antibiotics for the treatment of various bacterial pathogens-related infections worldwide. As per the Centers for Disease Control and Prevention (CDC), antibiotics such as Benzathine penicillin G can cure the early stages of syphilis with a single injection. CDC recommends 3 doses of long-acting Benzathine penicillin G at weekly intervals for latent syphilis of unknown duration. Moreover, Azithromycin as a single 2-g oral dose is found to be effective for treating primary and secondary syphilis among certain populations. Hence, the increasing need for the development of more such antibiotics along with the skyrocketing pharma research and development (R&D) research & development is expected to propel the antibiotics segment growth in the projected period. It was found that R&D spending in the pharmaceutical industry amounted to USD 238 billion globally in 2021.
Diagnosis (Lesions Testing, Dark-Field Microscopy)
The global nonvenereal syphilis treatment market is also segmented and analyzed for demand and supply by diagnosis into lesions testing, dark-field microscopy, and others. Amongst these segments, the lesion testing segment is expected to garner a significant share in the year 2037. The major factors applicable to the growth of the segment include the rising number of infection-related deaths worldwide as well as the increasing prevalence of genital ulcers disease (GUD) and the rising need to test nonvenereal genital lesions such as vitiligo, pearly penile papule, fixed drug eruptions, scabies, scrotal dermatitis, lichen planus besides other genital dermatoses such as sebaceous cyst, psoriasis, lichen sclerosus, plasma cell balanitis or Zoon's balanitis, granuloma annulare, lichen nitidus, lymphangioma circumscriptum, Paulo-necrotic tuberculid, squamous cell carcinoma, and tinea infections as they are spreading at a faster pace. It was found that infection-related deaths globally reached nearly 13·7 million deaths in 2019. All these factors are driving the rising investment in the development of accurate lesion testing, lesion biopsy, and skin biopsy techniques, expanding the scope of segment growth.
Our in-depth analysis of the global market includes the following segments:
|
By Treatment |
|
|
By Diagnosis |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Nonvenereal Syphilis Treatment Industry - Regional Synopsis
Middle East and Africa Forecast
Middle East and Africa industry is likely to hold largest revenue share by 2037, The growth of the market can be attributed majorly to the existence of nonvenereal syphilis in regions of West Africa, the Mediterranean, and the Sahara owing to the lack of sanitization as well as the hot and humid climate. Moreover, the rising awareness of syphilis infections, along with its increasing prevalence is further expected to boost the market growth in this region. As per projections over 10 million people are infected with syphilis worldwide with the majority of these infected people found in sub-Saharan Africa and Asia. In African regions, especially in remote regions of Africa, the living conditions of the Africans in areas such as the Kimberley are considered to be conducive to the spread of Treponema species, hence it is expected that the market in this region will mark growth in the projected years.
APAC Market Statistics
The Asia Pacific nonvenereal syphilis treatment market, amongst the market in all the other regions, is projected to hold the second largest share in the projected years. The market growth in the projected years majorly includes the prospering travel and tourism, sex industry, migration of workers, and poor control measures as well as the rising emergence of syphilis, bejel, yaws, and pinta as a severe public health issue in underdeveloped & developing countries of Asia, South Asia, and the Western Pacific islands. The travel and tourism industry which contributed nearly USD 143 billion to the GDP in Southeast Asia in 2021, has its own pros and cons. Tourism not also attracts tourists but also results in the transmission of various pathogens from one country to another. Thus, the increasing awareness campaigns as well as the growing government spending on the development of proper diagnostic facilities together with rising investment in drug development to curb the spread of such diseases in middle and low-income countries is further expected to escalate the regional market growth.
North American Market Forecast
Furthermore, the market in North America, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2037. The growth of the market can be attributed majorly to the gradual spread of bejel on islands of the region such as in Cuba, as well as increasing government initiatives to curb the spread of Treponema pallidum subsp. endemicum (TEN) along with the development of rapid diagnostic tests (RDTs) that can better distinguish an active infection of syphilis, bejel, or yaws to facilitate early treatment to the patients is expected to boost the nonvenereal syphilis market in the region in the projected years.
Companies Dominating the Nonvenereal Syphilis Treatment Landscape
- Pfizer, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Novartis International AG
- Sanofi S.A.
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Otsuka Pharmaceutical Co., Ltd.,
- Abbott Laboratories
- Cipla Limited
Recent Developments
-
Cipla Limited a multinational pharmaceutical company joint hands with Kemwell Biopharma Private Limited, a leading global CDMO, to make cost-effective biotherapeutics.
-
Sandoz, a subsidiary of Novartis, expanded its portfolio in manufacturing antibiotics with the acquisition of the Cephalosporin antibiotics business of GSK.
Author Credits: Radhika Pawar
- Report ID: 3569
- Published Date: Dec 23, 2024
- Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
